The trial evaluates survival outcomes for recurrent head and neck squamous cell carcinoma post-radiation therapy, comparing ...
Neoadjuvant Opdivo with chemotherapy significantly improves overall survival in resectable NSCLC compared to chemotherapy alone, as shown in the CheckMate-816 study. The study's primary endpoints, ...
Neoadjuvant pembrolizumab achieved a 71% pCR rate in desmoplastic melanoma, surpassing expectations for neoadjuvant anti–PD-1 treatment. The 3-year relapse-free survival rate was 74%, and the overall ...
We would like to comment on Schuler et al., on their well-designed randomized phase II NEOpredict-Lung study (NCT04205552) which was published in Nature Medicine. The main objective of this study was ...
The addition of atezolizumab to standard neoadjuvant chemotherapy followed by adjuvant atezolizumab did not significantly improve event-free survival (EFS) in patients with stages II-III ...
Please provide your email address to receive an email when new articles are posted on . Neoadjuvant chemotherapy significantly lowered 90-day postoperative mortality for advanced ovarian cancer across ...
Tyvyt plus CRT achieved a 60% pCR rate, outperforming Tyvyt plus chemotherapy (13%) and CRT alone (47.3%). Neoadjuvant Tyvyt plus CRT may become a new standard of care for resectable, locally advanced ...
Researchers from the University of Chicago Medicine Comprehensive Cancer Center have demonstrated the potential of a novel ...
With Enhertu and Datroway, Daiichi Sankyo has made itself a top-tier player in antibody-drug conjugates. | With Enhertu and Datroway, Daiichi Sankyo has made itself a top-tier player in antibody-drug ...
The Neotorch randomized phase III clinical trial was designed to evaluate whether the addition of perioperative toripalimab [programmed cell death 1 (PD-1) inhibitor] to platinum-based chemotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results